Cardiac phenotype in hereditary transthyretin amyloidosis: correlations between fibril types and 99mTc-DPD uptakeShow others and affiliations
2026 (English)In: Scientific Reports, E-ISSN 2045-2322, Vol. 16, no 1, article id 9196
Article in journal (Refereed) Published
Abstract [en]
Variant transthyretin amyloidosis is a systemic disease. In Sweden, the Val30Met variant is the most prevalent. Val30Met presents in two phenotypes: an early-onset form dominated by polyneuropathy and a late-onset form frequently accompanied by cardiomyopathy. These phenotypes are associated with two amyloid fibril types. Type A fibrils, contain both fragmented and full-length transthyretin, whereas type B fibrils contain only full-length transthyretin. Fibril type has been linked to differences in cardiac tracer uptake on 99mTc-DPD scintigraphy. A total of 152 patients with confirmed variant transthyretin amyloidosis evaluated at Umeå University Hospital, Sweden, were included. Age at disease onset and cardiac involvement, investigated by echocardiography, Troponin-T, and NT-proBNP, were assessed in relation to fibril type in abdominal fat and scintigraphic findings. Eighty-five patients had type A fibrils and sixty-seven had type B fibrils. Type A patients were older at diagnosis and had pathologic scintigraphies and more severe cardiac involvement. A subset of type B patients (15%) exhibited cardiac tracer uptake and had cardiac characteristics and age at disease onset similar to those with type A fibrils. Even though there was a strong correlation with findings in abdominal fat pad biopsies, results from 99mTc-DPD scintigraphy correlated better with clinical phenotype.
Place, publisher, year, edition, pages
Nature Publishing Group, 2026. Vol. 16, no 1, article id 9196
Keywords [en]
99mTc-DPD, Cardiomyopathy, fibril type, Transthyretin amyloidosis, Val30Met
National Category
Cardiology and Cardiovascular Disease
Identifiers
URN: urn:nbn:se:umu:diva-251812DOI: 10.1038/s41598-026-43816-xISI: 001717438000005PubMedID: 41839977Scopus ID: 2-s2.0-105033617086OAI: oai:DiVA.org:umu-251812DiVA, id: diva2:2055451
Funder
Swedish Research Council, 2022-01254Swedish Heart Lung Foundation, 2301742026-04-242026-04-242026-04-24Bibliographically approved